View source for 18614107. METHODS FOR TREATING LYMPHOMA simplified abstract (NORTHWESTERN UNIVERSITY)

=METHODS FOR TREATING LYMPHOMA=


==Organization Name==

[[:Category:NORTHWESTERN UNIVERSITY|NORTHWESTERN UNIVERSITY]]


[[Category:NORTHWESTERN UNIVERSITY]]

==Inventor(s)==

[[:Category:Jaehyuk Choi of Chicago IL (US)|Jaehyuk Choi of Chicago IL (US)]][[Category:Jaehyuk Choi of Chicago IL (US)]]

[[:Category:Jay Carroll Daniels of Chicago IL (US)|Jay Carroll Daniels of Chicago IL (US)]][[Category:Jay Carroll Daniels of Chicago IL (US)]]

[[:Category:Jurgen Ruland of München (DE)|Jurgen Ruland of München (DE)]][[Category:Jurgen Ruland of München (DE)]]

[[:Category:Tim Wartewig of Higganum CT (US)|Tim Wartewig of Higganum CT (US)]][[Category:Tim Wartewig of Higganum CT (US)]]

==METHODS FOR TREATING LYMPHOMA - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18614107 titled 'METHODS FOR TREATING LYMPHOMA

**Simplified Explanation:**
The patent application describes a method for treating lymphoma by administering a PD-1 pathway agonist to a subject in need.

**Key Features and Innovation:**
* Treatment method for lymphoma using a PD-1 pathway agonist
* Administering an effective amount of the agonist to the subject
* Targeting the PD-1 pathway to treat the condition

**Potential Applications:**
This technology could be used in the treatment of various types of lymphoma and potentially other cancers that involve the PD-1 pathway.

**Problems Solved:**
The technology addresses the need for more effective treatments for lymphoma by targeting the PD-1 pathway, which plays a role in the immune response to cancer cells.

**Benefits:**
* Improved treatment options for lymphoma patients
* Targeted therapy with potentially fewer side effects
* Potential for increased survival rates and better outcomes

**Commercial Applications:**
The technology could have significant commercial applications in the pharmaceutical industry, leading to the development of new cancer treatments and potentially improving patient outcomes.

**Questions about Lymphoma Treatment with PD-1 Pathway Agonists:**
1. How does targeting the PD-1 pathway specifically help in treating lymphoma?
   - Targeting the PD-1 pathway can enhance the immune response against cancer cells, potentially leading to better treatment outcomes.
2. Are there any potential side effects associated with using PD-1 pathway agonists for lymphoma treatment?
   - While generally well-tolerated, PD-1 pathway agonists can cause immune-related side effects that need to be monitored during treatment.


==Original Abstract Submitted==

Provided herein is a method for treating a lymphoma in a subject in need thereof, comprising administering to the subject an effective amount of at least one PD-1 pathway agonist.



[[Category:A61K31/436]]
[[Category:A61K31/18]]
[[Category:A61K31/7004]]
[[Category:A61P35/00]]
[[Category:CPC_A61K31/436]]